Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$223.95 USD

223.95
2,222,026

-0.79 (-0.35%)

Updated May 3, 2024 04:00 PM ET

After-Market: $223.14 -0.81 (-0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEV

Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Cencora (COR) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Indrajit Bandyopadhyay headshot

What's in Store for These 4 Medical Device Stocks in Q1 Earnings?

by Indrajit Bandyopadhyay

Here is a sneak peek into how the four medical device stocks, COR, GKOS, ARAY and SRDX, might fare in their quarterly results slated to be release tomorrow.

Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised

by Zacks Equity Research

Cencora's (COR) second-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Cencora (COR) Q2 Earnings Top Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 4.11% and 2.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Can the 4 Medical Device Stocks Hit Targets This Earnings Season?

by Debanjana Dey

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, GKOS, SRDX and ARAY are placed ahead of their earnings releases.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Cencora (COR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Cencora (COR) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Cencora's (COR) second-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEV

Philips' (PHG) Zenition 30 to Boost Image-Guided Surgeries

by Zacks Equity Research

Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Virtu, Coinbase, General Mills in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Reasons Why You Should Retain Masimo (MASI) Stock for Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits

by Zacks Equity Research

CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.

GE HealthCare's (GEHC) Voluson to Aid Women's Health Imaging

by Zacks Equity Research

GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.

Intuitive Surgical (ISRG) Q1 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.

Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis

by Zacks Equity Research

Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.

Why You Should Add Inspire Medical (INSP) to Your Portfolio

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

by Zacks Equity Research

IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays

by Zacks Equity Research

PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.

GE HealthCare (GEHC), RSNA Unite to Aid Breast Cancer Imaging

by Zacks Equity Research

GE HealthCare (GEHC) and RSNA collaborate to provide radiologists at Muhimbili National Hospital a test mammography technology and advanced imaging training to aid in the treatment of breast cancer.

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.